Mashup Score:11
OncLiveDurvalumab Plus Chemotherapy With or Without Olaparib Improves PFS in Advanced Endometrial Cancer - 2 days
Mashup Score:11
Twitter Feed: OncLive.com
Mashup Score:10
OncLiveTelephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors - 3 days
Mashup Score:10
A telephone and web-based weight loss intervention was successful in helping patients with breast cancer who were overweight or obese lose weight—which can ultimately...
-
A telephone and web-based weight loss intervention was successful in helping patients w/ breast cancer who were overweight or obese lose weight—which can ultimately lead to improved outcomes. #oncology #bcsm https://t.co/EEV4AYmvx9 - view on twitter
Mashup Score:9
OncLiveAdvances Across Urothelial Carcinomas Highlight Need for Shared Decision-making - 1 week
Mashup Score:9
As longer-term data read out for established regimens in urothelial cancer and up-and-coming therapeutics inch toward approval, optimizing treatment approaches relies on buy-in from...
-
Advances Across Urothelial Carcinomas Highlight Need for Shared Decision-making @PGrivasMDPhD @apolo_andrea @shilpaonc #blcsm https://t.co/bq9NIgWZYC - view on twitter
More coverage:
#blcsm
Mashup Score:8
OncLiveDr Harding on the Rationale for Targeting FGFR2 in Cholangiocarcinoma and Biliary Tract Cancers - 1 week
Mashup Score:8
James Harding, MD, discusses the rationale for targeting FGFR2 in patients with cholangiocarcinoma and biliary tract...
-
WATCH: James Harding, MD, of @MSKCancerCenter, discusses the rationale for targeting FGFR2 in patients with cholangiocarcinoma and biliary tract cancers. https://t.co/rwbGttBeLa - view on twitter
Mashup Score:8
OncLiveThe National Institute for Health and Care Excellence has recommended the combination of pembrolizumab and lenvatinib for use in previously treated patients with advanced...
-
The NICE has recommended pembrolizumab & lenvatinib for use in previously treated pts w/ advanced or recurrent endometrial cancer whose cancer has progressed on or after platinum-based chemotherapy & who cannot have curative surgery or radiotherapy #gyncsm https://t.co/hvbPZFDi2N https://t.co/hvbPZFDi2N - view on twitter
More coverage:
#gyncsm
Mashup Score:7
OncLiveThe combination of durvalumab and platinum-based chemotherapy, followed by maintenance therapy with either durvalumab plus olaparib or durvalumab alone, elicited a statistically significant and...
-
Durvalumab Plus Chemotherapy With or Without Olaparib Improves PFS in Advanced Endometrial Cancer @ShannonWestin @MDAndersonNews #gyncsm https://t.co/6uLrdfm4d5 - view on twitter
More coverage:
#gyncsm
Mashup Score:7
OncLiveClaudin-18.2 Emerges as a Novel Therapeutic Target in GI Malignancies - 3 days
Mashup Score:7
CLDN18.2 has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer, gastroesophageal junction cancer, esophageal cancer, and...
-
CLDN18.2 has become a promising target for pts w/ digestive malignancies, such as gastric cancer, GEJ, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues and abnormal overexpression. @KoheiShitara #oncology https://t.co/5Pew1ED6yd https://t.co/5Pew1ED6yd - view on twitter
More coverage:
#oncology
Mashup Score:7
OncLiveThe National Institute for Health and Care Excellence has recommended the combination of pembrolizumab and lenvatinib for use in previously treated patients with advanced...
-
The NICE has recommended pembrolizumab & lenvatinib for use in previously treated pts w/ advanced or recurrent endometrial cancer whose cancer has progressed on or after platinum-based chemotherapy & who cannot have curative surgery or radiotherapy #gyncsm https://t.co/fmM1GDKU3j - view on twitter
More coverage:
#gyncsm
Mashup Score:7
OncLiveEMA Recommends Approval of Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC - 2 days
Mashup Score:7
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab as neoadjuvant therapy in combination with platinum-based...
-
The EMA has recommended the approval of nivolumab as neoadjuvant therapy w/ platinum-based chemotherapy for patients with resectable NSCLC at high risk of recurrence and tumor cell PD-L1 expression of at least 1%. @EMA_News #lcsm https://t.co/HwF2bw4Wsb https://t.co/HwF2bw4Wsb - view on twitter
More coverage:
#lcsm
Mashup Score:6
OncLiveNCCN Guidelines List Ropeginterferon Alfa-2b as Preferred Treatment in Polycythemia Vera - 3 days
Mashup Score:6
The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b-njft as a preferred treatment option for patients...
-
The NCCN Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b-njft as a preferred treatment option for patients with high- and low-risk polycythemia vera, irrespective of treatment history. #mpnsm #oncology https://t.co/lsOuLHaKaV - view on twitter
The combination of durvalumab and platinum-based chemotherapy, followed by maintenance therapy with either durvalumab plus olaparib or durvalumab alone, elicited a statistically significant and...
Durvalumab + platinum-based chemotherapy, followed by maintenance therapy w/ either durvalumab + olaparib or durvalumab alone, elicited an improvement in PFS in newly diagnosed, advanced/ recurrent endometrial cancer. @ShannonWestin @MDAndersonNews #gyncsm https://t.co/PCR62rkQir - view on twitter